東寶生物(300239.SZ)業績快報:2021年度淨利潤升93.47%至3569.62萬元
格隆匯3月23日丨東寶生物(300239.SZ)披露2021年度業績快報,報吿期內,公司實現營業收入6.12億元,較上年同期增長36.39%;實現營業利潤4087.83萬元,較上年同期增長106.91%;實現利潤總額4072.54萬元,較上年同期增長107.10%;實現歸屬於上市公司股東淨利潤3569.62萬元,較上年同期增長93.47%。
變動主要原因:
1、明膠系列產品業務穩步發展,市場需求向好,銷量、銷售收入較上年同期實現進一步增長,銷售利潤相應增加。
2、受益於公司“膠原+”系列產品的不斷深入推廣,膠原蛋白系列終端產品業務穩步發展,銷售收入提升,銷售利潤相應增加。
3、公司2021年度以非同一控制下的企業合併方式收購益青生物控股權,益青生物納入公司合併報表範圍影響營業收入略有增加。
4、報吿期內公司非經常性損益對淨利潤的貢獻金額為961.59萬元,較上年同期659.29萬元增加302.30萬元,增長45.85%。非經常性利潤貢獻主要是公司收到的再融資政府獎勵資金、高新技術企業認定獎勵資金、受疫情影響的政府補貼資金以及遞延收益攤銷轉當期損益等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.